pharma · B-Cell Non-Hodgkin Lymphoma
Qian Wenbin
Qian Wenbin is a pharma organization headquartered in CN. Primary therapeutic focus areas include B-Cell Non-Hodgkin Lymphoma. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 4
- Patents
- 0
CAR T cells
Phase 1 · small molecule · B-Cell Non-Hodgkin Lymphoma
CAR T cells for B-Cell Non-Hodgkin Lymphoma is a Phase 1 program (small_molecule) at Qian Wenbin with 1 ClinicalTrials.gov record(s).
Internal code CT1190B-CG1101_01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Qian Wenbin
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- B-Cell Non-Hodgkin Lymphoma
- Status
- active
- Trials
- 1